Press Releases
Freenome Announces Topline Results for PREEMPT CRC® to Validate the First Version of its Blood-Based Test for the Early Detection of Colorectal Cancer
April 2, 2024
– Study met all primary endpoints, including 79.2% sensitivity for colorectal cancer (CRC) and 91.5% specificity for non-advanced colorectal neoplasia – – PREEMPT CRC, the ...
Freenome Initiates PROACT LUNG Clinical Study for the Early Detection of Lung Cancer Using Blood Test Developed on Multiomics Platform
December 12, 2023
– Registrational study targets enrollment of 20,000 individuals at high risk of lung cancer SOUTH SAN FRANCISCO, CA (Dec. 12, 2023) — Freenome, a privately ...
Walgreens and Freenome Establish Partnership to Increase Diversity in Research for the Early Detection of Cancer
June 15, 2023
DEERFIELD, Ill. & SAN FRANCISCO, June 15, 2023 — Walgreens and Freenome today announced a multi-year relationship to advance clinical studies of Freenome’s blood-based tests for ...
Freenome Presents a Subject Population Analysis of a Clinical Study Using a Multiomics Blood Test for the Early Detection of Colorectal Cancer
March 6, 2023
– PREEMPT CRC is a large, representative registrational study for the early detection of colorectal cancer – Findings presented at the Western Colorectal Cancer Consortium Conference ...
Freenome Presents Research Highlighting the Promise of Identifying Drug-Response Biomarker for DLBCL Patients
December 12, 2022
Freenome’s comprehensive multiomics and multi-feature computational approach provides insights for therapy development and patient efficacy SOUTH SAN FRANCISCO, Dec. 12, 2022 — Freenome, a privately ...